Switch theme
Sign up to access all valuation multiples
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
2010
80
LTM Revenue $11.8M
LTM EBITDA n/a
$200M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Verastem has a last 12-month revenue of $11.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Verastem achieved revenue of $10.0M and an EBITDA of -$126M.
Verastem expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Verastem valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $10.0M | XXX | XXX | XXX |
| Gross Profit | $2.6M | n/a | XXX | XXX | XXX |
| Gross Margin | Infinity% | NaN% | XXX | XXX | XXX |
| EBITDA | -$83.2M | -$126M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -1259% | XXX | XXX | XXX |
| Net Profit | -$73.8M | -$87.4M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -874% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Verastem's stock price is $5.
Verastem has current market cap of $246M, and EV of $200M.
See Verastem trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $200M | $246M | XXX | XXX | XXX | XXX | $-3.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Verastem has market cap of $246M and EV of $200M.
Verastem's trades at 16.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Verastem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Verastem and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $200M | XXX | XXX | XXX |
| EV/Revenue | 20.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVerastem's NTM/LTM revenue growth is 180%
Verastem's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.6M for the same period.
Over next 12 months, Verastem's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Verastem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Verastem and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1259% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1079% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 813% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1250% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verastem acquired XXX companies to date.
Last acquisition by Verastem was XXXXXXXX, XXXXX XXXXX XXXXXX . Verastem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Verastem founded? | Verastem was founded in 2010. |
| Where is Verastem headquartered? | Verastem is headquartered in United States of America. |
| How many employees does Verastem have? | As of today, Verastem has 80 employees. |
| Who is the CEO of Verastem? | Verastem's CEO is Mr. Daniel Paterson. |
| Is Verastem publicy listed? | Yes, Verastem is a public company listed on NAS. |
| What is the stock symbol of Verastem? | Verastem trades under VSTM ticker. |
| When did Verastem go public? | Verastem went public in 2012. |
| Who are competitors of Verastem? | Similar companies to Verastem include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Verastem? | Verastem's current market cap is $246M |
| What is the current revenue of Verastem? | Verastem's last 12-month revenue is $11.8M. |
| What is the current EV/Revenue multiple of Verastem? | Current revenue multiple of Verastem is 16.9x. |
| Is Verastem profitable? | Yes, Verastem is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
